Better Pharma Dividend Stock: Novartis vs. Merck
Merck's outlook is bright despite challenges to its core franchises. Novartis is performing well despite a recent major patent cliff.
Open original sourceLoading market dashboard
Merck's outlook is bright despite challenges to its core franchises. Novartis is performing well despite a recent major patent cliff.
Open original source